Pleiotropy across the 8q24 region is perhaps the most intriguing of the genome-wide association findings relating to cancer. This region of chromosome 8 is a gene desert, far from any recognized genes. Guarrera et al., whose work is reported in this issue (Am J Epidemiol. 2012;175(6):479-487), took an epidemiologic approach to learn more about the 8q24 region. They capitalized on their ascertainment of other endpoints in members of the cohort at the Turin site of the European Prospective Investigation Into Cancer and Nutrition to investigate multiple outcomes for additional pleiotropic effects in the 8q24 region. Alternative design options might involve genotyping of more variants, incorporation of more cases, or use of a single control group close to the size of the most common case group. Their analytic methods reflect the uncertainty of the underlying biology. The findings sharpen the scientific question about how variation in the 8q24 region affects pathogenesis. The genome-wide association effort is possible because of the economy of scale afforded by extremely dense genotyping. Strict adherence to the hypothesis-driven approach would ignore information that is obtainable at a trivial cost. The genome-wide association strategy tests whether agnostic data-mining methods can advance knowledge alongside or even in place of the standard hypothesis-driven approach, which is the conventional scientific method children learn in kindergarten and onward, even through graduate school and beyond.
The underlying philosophy of genome-wide association (GWA) is to assume as little as possible and let massive amounts of data provide scientific evidence. Most reports of an association between single nucleotide polymorphisms (SNPs) that were chosen for study because they were thought to be the ones most likely to be associated with disease were not confirmed (1) . Treating every part of the genome and every marker equivalently, rather than making presumptions about the likelihood of associations between regions of the genome or specific variants and disease, was part of the agnostic philosophy.
The main design consideration was to maximize total power across the genome as efficiently and with as few markers as possible (2) . Instead of genotyping all common variants, investigators used chips that genotyped a subset of tagging markers that were chosen based on correlations with unmeasured variants. A competing paradigm that was not adopted by chip manufacturers would have involved genotyping of all variants in coding regions, splice junctions, and promoter regions only (3); statistical power would be higher and the chance of a false negative could be lower and sample size could be smaller for each of these variants because of larger prior probabilities of associations or much less extreme Bonferroni correction with a restricted set of variants (3). The power to find other variants, including markers in the noncoding region of 8q24, would be close to 0, however. Compromise or staged plans might have performed better than either one.
Based on the experience with candidate genes (1) and legitimate fear of the poor record of data mining generally, the big analytic concern was false positives. The field adopted one solution: control the family-wide error rate, or the chance that a single false positive conclusion would be reached at the standard significance (a) level of 5%. This is the Bonferroni method (4). Because a million-fold decrease in a increases the required sample size by only one order of magnitude, large studies that involve planned replication (4) or pooling of several sequential studies (5) can provide reasonable power for loci with the low odds ratios typically observed in GWA studies. The potential loss from false negatives affected sample size but had no impact on the data analysis; the GWA strategy treats a study outcome of 0 true positives and 0 false positives as superior to an outcome of 50 true positives and 1 false positive.
The GWA effort has found many variants for cancer and other diseases, including SNPs around the telomerase transcriptase gene (TERT; chromosomal region 5p15.33) and around the zinc finger 1 gene (JAZF1; 7p15.5) associated with risks of several cancers and other diseases and with height. Pleiotropy across the 8q24 region (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) is perhaps the most intriguing of the GWA findings related to cancer. Early GWA studies found overwhelming statistical evidence of an association between several markers in this region of chromosome 8 and both breast and prostate cancers. This finding in a region with no genes nearby, or a ''gene desert,'' was particularly surprising, especially in light of the lack of linkage signals from such regions for mendelian diseases; of course, our ability to study intergenic regions has increased (3). Any association in an intergenic region violates the central dogma of genetics: DNA produces RNA, RNA produces protein, and protein affects biologic functioning, including disease pathogenesis. In the absence of nearby genes, how do variations at many loci in this 8q24 region affect several different diseases?
Determining the next step after identifying an association between a SNP in a region like 8q24, about which little is known, and disease is necessarily harder than follow-up of a finding from a hypothesis-based approach, in which SNPs are chosen on the basis of at least some prior knowledge. Without background knowledge, no next step will be obvious, and the economy of scale of the initial positional cloning no longer helps. Indeed, laboratory scientists have been reluctant to follow-up on GWA findings because the associations identified to date are small, the precise genotypes and phenotypes are generally unknown, and the scope of the methods required and the payoff are so uncertain. The estimated effects will be greater when the true causal variant and the subset of disease affected, if any, are identified, as statisticians and epidemiologists noted half a century ago in a different context (18) . The one possible clue about 8q24 is its relative proximity to the potent oncogene myc. Nonetheless, the 8q24 region would be assigned the lowest priority in a hypothesisbased search, and the prior distributions of the strength of association in Bayesian approaches in the region would assign less weight to a strong association than to even anonymous variants in the exome.
The early GWA study associations between variants in the 8q24 region and cancer motivated efforts to increase understanding of genetic epidemiology and to discover underlying biologic mechanisms. Approximately 100 recent publications described attempts to replicate in different study populations the association between the 8q24 region and different types of cancer. Individual epidemiologic studies and consortia assessed gene-environment interactions or associations with several cancer sites and other diseases, but these studies have limited power, especially after adjustment for multiple comparisons. Experimental studies aimed at mechanistic understanding focused on regulation of myc. Resequencing efforts have been focused on the search for additional variants that might be causal, perhaps acting as enhancers or regulatory elements that control gene and RNA expression. A number of reviews, editorials, and commentaries have touched on the intriguing pleiotropic effects of the 8q24 region.
Another large group of publications has linked the 8q24 region to a variety of noncancer disorders, including congenital defects and psychological disorders. Guarrera et al. (19) , whose work is reported in this issue of the Journal, also took an epidemiologic approach. They capitalized on their ascertainment of other endpoints in members of the cohort at the Turin site of the European Prospective Investigation Into Cancer and Nutrition to investigate multiple outcomes for additional pleiotropic effects in the 8q24 region. They found correlations-not with a genome-wide significance criterion, but with more compelling evidence than was required in the candidate-gene era-for several associations.
The Turin team faced several design and analytic issues. Our discussion of these issues is general, aimed at informing researchers in similar circumstances rather than judging the design and analysis decisions these investigators made under the constraints of available data and resources.
Genotyping of all cohort members is inefficient for studies of a single rare disease and likely also for studies of many rare diseases at once. A case-control design, including case-cohort design, features a number of controls approximately equal to the sample size of the largest case group and guarantees a 1:1 or greater control-to-case ratio for all case groups when using common controls. The savings from using DNA for fewer people might have allowed genotyping of more variants and thereby increased the statistical power for some unmeasured variants in the region while maintaining the same study cost. More genotyped markers also allow investigation of more complex epistatic effects.
An alternative design strategy (or a follow-up to this study) would involve pooling of study data with that from other European Prospective Investigation Into Cancer and Nutrition sites or other studies with data on the outcomes under investigation and either genotype data, ability to impute markers successfully in this 8q region, or DNA for more genotyping. A formal comparison of the tradeoffs among larger sample size, different case-control sampling schemes, and more measured and imputed SNPs depends on the linkage disequilibrium structure, displayed in the figure by Guarrera et al. (19) , and the true but still unknown effect of different variants in the region on all of the endpoints of interest. For now, investigators can look at the existing evidence, speculate intelligently (perhaps with some formal quantification), consider the benefits and costs, and decide.
The focus of GWA studies has been on testing rather than estimation; the strategy of using markers instead of the disease-causing SNPs themselves means all estimates are attenuated, as any misclassified exposure would be, so estimates are not intrinsically meaningful. Alternative approaches to standard testing can be helpful. The Turin team used the false-positive report probability method (20) to complement confidence intervals. SNPs in the 8q24 region are no longer anonymous; the chance that they affect noncancer diseases might be enhanced by the fact that they have been shown to affect more than one kind of cancer, but no one can say by how much. The authors' use of varying prior probabilities (19) reflects the lack of confidence of individuals and the lack of consensus among study teams, not to mention readers, about how to quantify, even crudely, subjective knowledge about these questions before beginning analysis of this study. The range of false-positive report probability values reported is a reminder of the uncertainty.
The Bayesian false discovery probability method (21) is an alternative approach to false-positive report probability. The Bayesian false discovery probability uses the ratio of the loss of false-positive and false-negative reports explicitly and allows specification of the prior distribution of the true odds ratio, not just a probability as in false-positive report probability. Reaching a decision on the prior probability is much easier than reaching a decision on the full prior distribution, and arbitrary choices of a distribution are no more useful than choices of a single point to characterize subjective knowledge. Other analytic options, including determination of false discovery rates using methods like the HochbergBenjamini technique (22), probably would not help in an investigation of pleiotropy because they require exchangeable hypotheses (23) . Empirical Bayes assumptions of exchangeability seem justifiable at the GWA stage and allow estimates of effect that do not exaggerate the magnitude of the association; knowledge about pleiotropy in the 8q24 region may justify incorporation of what we have learned into a hierarchical model (24, 25) or use of correlated priors in false-positive report probability or the Bayesian false discovery probability.
Our limited knowledge about the genome would not have led to identification of the interesting aspects of 8q24 using a fully hypothesis-based approach. Even though alternative approaches might not have drawn special attention to the associations in the 8q24 region, choosing different variants to genotype and accounting for differences in prior probability, whether based on association or linkage signals in the region or using our understanding of DNA and amino acids, might have reduced cost or uncovered associations missed in the first GWA studies.
A more complex question than the credibility of the individual positive findings reported by the Turin group is that of the level of certainty about pleiotropy in the 8q24 region provided by the evidence here. Creating a hypothesis and statistical procedure to evaluate these kinds of complex sets of evidence seems impossible with our current genomic understanding, far harder than deciding whether we should be shocked to see the same person hitting the jackpot in the lottery multiple times (26) , a scenario for which we have a presumptive probabilistic model.
The big question from the genomic side is how to explain the pleiotropic effect in an intergenic region. A cluster of SNPs in a genic region would suggest common etiologic pathways, such as lipid metabolism, as possible explanations for the relations between apolipoprotein E and cardiovascular disease and Alzheimer disease (27, 28) . Efforts to determine whether the presence of the 8q24 variants, even though they are located far from any genes, have regulatory effects or affect expression in ways that affect pathways to the various conditions may be part of one approach.
We have now known for many years that mutations in the breast cancer 1 and breast cancer 2 genes (BRCA1 and BRCA2) confer a very high risk of breast and ovarian cancers. Nonetheless, despite continuing efforts (29) , no promising primary prevention or molecular intervention (beyond expensive and not fully sensitive mutation screening via DNA testing, possibly followed by prophylactic surgery) is available. It is unrealistic to expect that GWA study findings will lead to rapid translational breakthroughs, given the much smaller established effects of markers on absolute and relative risk. Thus, the main outcome from this work will likely be scientific: The totality of the various findings sharpens the question about the complex effects of 8q24 variants. In turn, this kind of extension of GWA findings may eventually help in a small but perhaps profoundly important ways to understand the underlying biology behind the central dogma.
Scientific understanding of the 8q24 story requires more than looking at lists of regions, genes, and variants associated with different diseases in a database. Full understanding will explain how and why some SNPs affect specific diseases and why other SNPs do not, as well as why some outcomes are associated and others are not. In the meantime, the evidence about the unique and surprising pleiotropic effects of the 8q24 region clearly justifies further scientific evaluation.
